TABLE 3.

Patient Populations That May Benefit Most From Treatment With an SGLT2 Inhibitor Instead of or in Addition to Incretin-Based Therapies

Patients likely to benefit from treatment: • Patients with normal kidney function • Patients intolerant to metformin • Patients requiring add-on therapy to metformin because they are not at goal • Newly diagnosed patients with an A1C >9% requiring initial combination therapy with metformin plus a second antihyperglycemic agent • Patients requiring a third antihyperglycemic agent because they are not at goal with dual therapy

Patients for whom canagliflozin should be used with caution: • Patients with moderate renal impairment • Elderly patients • Patients prone to genital mycotic infections • Patients taking loop diuretics or with other risk factors for dehydration